Jeff Liter

Jeff is a seasoned CEO with a proven track record at profitably growing emerging companies and business divisions. He has raised over $10M in seed capital from angel investors to start four different companies which he then led to becoming profitable or acquired.  He recently led Luminary Therapeutics to its first FDA cleared IND with a non-viral gene modified therapy. Was the CEO of B-MoGen Biotechnologies and was the former COO of PCT a leading CDMO in the cell therapy industry. 

  • Successfully developed and sold a Cell Therapy tools company in three years 
  • Former Chief Operating Officer of Progenitor Cell Therapy 
  • Processed over 25 clinical trials for respective therapy customers 
  • Responsible for tech transferring Kite’s T-Cell therapy out of the NIH, Novartis’ cell therapy out of U-Penn and Adaptimmume’s cell therapy out of U Penn 

Cell processing / manufacturing experience that spans Phase I, II, & III therapies